MIRM logo

MIRUM PHARMACEUTICALS INC

MIRMNASDAQ
🏆 #1273 by market capEarnings Nov 4 · PostUS Equity
$517.07▲ $19.34 (+3.74%)
Simulated price
🔔
Track MIRM
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.7%
7d▲ 467.0%
14d▲ 450.7%
30d▲ 430.7%
ytd▲ 554.9%
1y▲ 609.8%
🏦Market Cap
$5.36B
Small Cap
📈Revenue Growth (YoY)
+54.7%
High Growth
📊Gross Margin
81.7%
High
💵FCF Margin
-74.1%
Thin
⚖️P/S Ratio
8.7x
Elevated
Otter Score
80
Good

Trading Snapshot

Day Range
$512.61 – $520.31
52-Week Range
$63.23 – $130.00
Volume
$3.77B
Avg Volume
$4.70B
Shares Outstanding
61.0M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$521M
Last Q Revenue
$176M
P/E Ratio
-6.0
P/S Ratio
8.7x
EPS (TTM)
$-13.57
Dividend Yield
0.00%
Dilution (1yr)
+3.8%

Why Investors Own MIRM

  • ✓High-growth profile — revenue up +26.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 48% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MIRM logo

MIRUM PHARMACEUTICALS INC

MIRM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$521M▲ +54.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
80.7%▲ +6.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −74.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$55M▲ +488.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.2M▲ +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$23M▲ +$72M YoY
StockOtter · stockotter.space

About MIRUM PHARMACEUTICALS INC

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$686.71
▲ +32.8% Upside
High Target$824.21
Low Target$644.67
Based on 33 analysts

Latest News & Updates

🚀
CNBC·2h ago

MIRUM PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift MIRM price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

MIRUM PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.